This month, education and research come together to treat cancer. The three hardest to detect cancers are broken down into the most common symptoms to watch out for. Scientific research has found that a strand of RNA may be the key to using our own immune system to treat cancer. A new immunotherapy has been created to use two mechanisms to enhance our own immune system to kill cancer.
The 3 Most “Undetectable” Cancers Revealed- and How to Spot Them Before it’s Too Late
Other forms of the disease can form and grow undetected for 10 years or more as one study found, making treatment that much more difficult. It’s not that these cancers have no symptoms at all, rather the initial symptoms are similar to that of other less serious health conditions reports The US Sun. The earlier cancer is detected and treated, the better the outcome. The three cancers discussed in this article are bowel cancer, pancreatic cancer, and ovarian cancer. Signs of bowel cancer include blood in stool or changes to bowel movements such as diarrhea or constipation. Some other signs of this cancer are sudden weight loss and abdominal or rectal pain. There are very few early signs in bowel cancer. In pancreatic cancer there is a very high mortality rate. Signs of pancreatic cancer are abdominal pain, back pain, weight loss, changes in bowel movements, vomiting, and jaundice. Ovarian cancer is a very common cancer and early detection is extremely important for survival. Most symptoms of ovarian cancer show in later stages due to it spreading. Signs to watch for are changes in bowel habits such as constipation and diarrhea. Click here for the full story.
Scientists Discover a Small Strand of RNA to be Key to Fighting Cancer with Our Immune System
A team of researchers at the University of Massachusetts Amherst has shown how a single, small strand of microRNA, known as let-7, governs the ability of T cells to recognize and remember tumor cells. This cellular memory is the basis for how vaccines work. Boosting cellular memory to recognize tumors could help improve cancer therapies reports Goodnews Network. T cells get activated when a pathogen like a virus enters the body. The T cells then become killer cells to get rid of the pathogen. Most T cells die off, but some remain to be turned on later if that pathogen is reintroduced into the body. These memory cells live for a long time. This is how vaccines work. A small amount of pathogen is injected causing this mechanism to occur. Cancer causes the T cells to turn off before they can attack the cancer cells or create a memory of the cells. This allows the cancer cells to metastasize. Scientists are hoping that this new knowledge can lead to developing better immunotherapy treatments for cancer. Click here for the full story.
Double Trouble for Cancer Tumors: The Dual-Action Immunotherapy Breakthrough
Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy reports SciTech Daily. This drug uses two mechanisms to slow the growth of tumors and increase patient survival. The small molecule drug increases immune sensitivity and immune cell activity. It blocks certain proteins, thereby making T cells and natural killer cells more effective at killing the tumor. At the same time, it makes the tumor more susceptible to the attack. Scientists hope by studying signal pathways they can find more advances for immunotherapy resistant cancers. Click here for the full story.
Dana Kaiser is a professional writer and a strong patient advocate, learning from experience during her 22-year career as a nurse.